MX2019014306A - Agente para reducir la cantidad de proteina beta amiloide. - Google Patents

Agente para reducir la cantidad de proteina beta amiloide.

Info

Publication number
MX2019014306A
MX2019014306A MX2019014306A MX2019014306A MX2019014306A MX 2019014306 A MX2019014306 A MX 2019014306A MX 2019014306 A MX2019014306 A MX 2019014306A MX 2019014306 A MX2019014306 A MX 2019014306A MX 2019014306 A MX2019014306 A MX 2019014306A
Authority
MX
Mexico
Prior art keywords
amyloid
protein
level
brain
protein level
Prior art date
Application number
MX2019014306A
Other languages
English (en)
Inventor
Hiroshi Kobayashi
Yoshihiko Matsumoto
Original Assignee
Fujifilm Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Toyama Chemical Co Ltd filed Critical Fujifilm Toyama Chemical Co Ltd
Publication of MX2019014306A publication Critical patent/MX2019014306A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un objeto de la presente invención es proporcionar un fármaco y un método que suprima el progreso de la enfermedad en la que aumenta la cantidad de proteína ß amiloide en el cerebro, como la enfermedad de Alzheimer. 1-(3-(2-(1-Benzothiophen-5-il)etoxi)propi l)azetidin-3-ol o una sal del mismo tiene el efecto de reducir la cantidad de proteína ß amiloide en el parénquima cerebral, y por lo tanto es efectivo como agente para reducir la cantidad de proteína ß amiloide en el cerebro. La enfermedad en la que aumenta la cantidad de proteína ß amiloide en el cerebro, como la enfermedad de Alzheimer, se puede prevenir o tratar mediante la administración de 1-(3-(2-(1-benzotiofen-5-il)etoxi)propil)azetidi na-3-ol o una sal del mismo.
MX2019014306A 2017-06-02 2018-06-01 Agente para reducir la cantidad de proteina beta amiloide. MX2019014306A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017109886 2017-06-02
JP2017128474 2017-06-30
PCT/JP2018/021226 WO2018221732A1 (ja) 2017-06-02 2018-06-01 アミロイドβ蛋白質量減少剤

Publications (1)

Publication Number Publication Date
MX2019014306A true MX2019014306A (es) 2022-06-09

Family

ID=64455735

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014306A MX2019014306A (es) 2017-06-02 2018-06-01 Agente para reducir la cantidad de proteina beta amiloide.

Country Status (14)

Country Link
US (2) US11666551B2 (es)
EP (1) EP3632429A4 (es)
JP (1) JP7256118B2 (es)
KR (1) KR20200003102A (es)
CN (1) CN110691595A (es)
AU (1) AU2018277983B2 (es)
BR (1) BR112019024983A2 (es)
CA (1) CA3067458C (es)
IL (1) IL270914A (es)
MX (1) MX2019014306A (es)
RU (1) RU2019138538A (es)
SG (1) SG11201911519UA (es)
WO (1) WO2018221732A1 (es)
ZA (1) ZA201907976B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018277981B2 (en) 2017-06-02 2021-04-08 Fujifilm Toyama Chemical Co., Ltd. Agent for preventing or treating spinocerebellar ataxia
WO2018221728A1 (ja) 2017-06-02 2018-12-06 富山化学工業株式会社 アルツハイマー型認知症予防または治療剤
NZ759585A (en) 2017-06-02 2022-02-25 Fujifilm Toyama Chemical Co Ltd Agent for preventing or treating brain atrophy
JP7227914B2 (ja) 2017-10-30 2023-02-22 富士フイルム富山化学株式会社 エモパミル結合タンパク質結合剤およびその利用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1019091A4 (en) 1997-09-05 2005-05-11 Human Genome Sciences Inc 50 SECRETED PROTEINS OF HUMAN ORIGIN
GB9824207D0 (en) 1998-11-04 1998-12-30 Zeneca Ltd Neurological disorders
AU2002344107B2 (en) 2001-10-19 2007-11-01 Toyama Chemical Co., Ltd. Alkyl ether derivatives or salts thereof
IL165589A (en) 2002-06-14 2012-04-30 Toyama Chemical Co Ltd Pharmaceutical preparation to improve brain function and use
EP1614419B1 (en) 2003-04-17 2012-08-08 Toyama Chemical Co., Ltd. Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof
SI2011796T1 (sl) 2006-04-26 2015-02-27 Toyama Chemical Co., Ltd. Induktor nevrogeneze ali terapevtska uäśinkovina proti nevropatiji, vsebujoäśa derivat alkilnega etra ali sol le-tega
US8119625B2 (en) 2006-04-26 2012-02-21 Toyama Chemical Co., Ltd. Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof
JP5624894B2 (ja) 2008-03-04 2014-11-12 ヴァーナリスアールアンドディー リミテッドＶｅｒｎａｌｉｓ Ｒ＆Ｄ Ｌｉｍｉｔｅｄ アゼチジン誘導体
FR2934596B1 (fr) 2008-07-30 2015-04-10 Trophos Nouveaux derives de l'oxime de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, et procede de preparation
WO2011057199A1 (en) 2009-11-06 2011-05-12 Adenios, Inc. Compositions for treating cns disorders
TR201907882T4 (tr) 2012-02-22 2019-06-21 Fujifilm Toyama Chemical Co Ltd 1-(3-(2-(1-Benzotiofen-5-il)etoksi)propil)azetidin-3-olü veya onun tuzunu içeren katı farmasötik bileşim
JP6397407B2 (ja) 2012-07-19 2018-09-26 ドレクセル ユニバーシティ 細胞タンパク質ホメオスタシスを調節するためのシグマ受容体リガンド
BR112015004942A2 (pt) 2012-10-01 2017-07-04 Hoffmann La Roche benzimidazóis como agentes ativos do snc
LT3100725T (lt) 2014-01-31 2020-08-10 Fujifilm Toyama Chemical Co., Ltd. Reabilitacijos poveikį po nervo pažeidimo sustiprinanti priemonė, apimanti alkileterio darinį arba jo druską
WO2015163318A1 (ja) 2014-04-25 2015-10-29 レジリオ株式会社 アルツハイマー病の治療剤を含む、神経細胞の軸索の機能不全が関与する疾患の治療剤
WO2015188368A1 (en) 2014-06-13 2015-12-17 Merck Sharp & Dohme Corp. Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles
WO2016051799A1 (ja) 2014-10-01 2016-04-07 学校法人同志社 ２－アミノヒドロキノン誘導体及びタウ凝集阻害剤
US20180022748A1 (en) 2015-02-02 2018-01-25 Ucb Biopharma Sprl 9h-pyrrolo-dipyridine derivatives
US20160324851A1 (en) 2015-05-07 2016-11-10 Axovant Sciences, Ltd. Methods of treating a neurodegenerative disease
WO2016199878A1 (ja) * 2015-06-11 2016-12-15 富山化学工業株式会社 シグマ受容体結合剤
JP6860502B2 (ja) 2015-12-25 2021-04-14 富士フイルム富山化学株式会社 １−（３−（２−（１−ベンゾチオフェン−５−イル）エトキシ）プロピル）アゼチジン−３−オールまたはその塩を含む錠剤
WO2018221728A1 (ja) 2017-06-02 2018-12-06 富山化学工業株式会社 アルツハイマー型認知症予防または治療剤
AU2018277981B2 (en) 2017-06-02 2021-04-08 Fujifilm Toyama Chemical Co., Ltd. Agent for preventing or treating spinocerebellar ataxia
CA3067456C (en) 2017-06-02 2023-03-14 Fujifilm Toyama Chemical Co., Ltd. Agent for preventing or treating tauopathy
NZ759585A (en) 2017-06-02 2022-02-25 Fujifilm Toyama Chemical Co Ltd Agent for preventing or treating brain atrophy
JP7227914B2 (ja) 2017-10-30 2023-02-22 富士フイルム富山化学株式会社 エモパミル結合タンパク質結合剤およびその利用

Also Published As

Publication number Publication date
CA3067458A1 (en) 2018-12-06
JP7256118B2 (ja) 2023-04-11
RU2019138538A (ru) 2021-07-09
EP3632429A1 (en) 2020-04-08
WO2018221732A1 (ja) 2018-12-06
AU2018277983A1 (en) 2019-12-19
BR112019024983A2 (pt) 2020-06-23
IL270914A (en) 2020-01-30
CN110691595A (zh) 2020-01-14
ZA201907976B (en) 2021-08-25
EP3632429A4 (en) 2020-06-10
KR20200003102A (ko) 2020-01-08
AU2018277983B2 (en) 2021-04-08
SG11201911519UA (en) 2020-01-30
US20230310371A1 (en) 2023-10-05
CA3067458C (en) 2022-11-01
US11666551B2 (en) 2023-06-06
JPWO2018221732A1 (ja) 2020-04-02
US20210137880A1 (en) 2021-05-13
RU2019138538A3 (es) 2021-07-09

Similar Documents

Publication Publication Date Title
MX2020011528A (es) Inhibidores heterociclicos sustituidos de ptpn11.
MX2019014306A (es) Agente para reducir la cantidad de proteina beta amiloide.
MX2019014300A (es) Agente para prevenir o tratar la tauopatia.
PH12016501600A1 (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
TN2017000134A1 (en) 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer's disease
EA201790271A1 (ru) Ингибиторы гликозидазы
JO3459B1 (ar) تركيبات صيدلانية لعلاج مرض الزهايمر
NZ759585A (en) Agent for preventing or treating brain atrophy
TN2017000144A1 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
MA41977B1 (fr) Imidazopyrazinones utilisées comme inhibiteurs de pde1
BR112018073951A2 (pt) forma cristalina inovadora de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida
PH12017501110A1 (en) Active compound combinations comprising a (thio)carboxamide derivative and fungicidal compound(s)
EA201792641A1 (ru) Ингибитор оси igfbp3/tmem219 и диабет
MA42776B1 (fr) Composés utiles pour l'inhibition du ror-gamma-t
NZ759647A (en) Agent for preventing or treating spinocerebellar ataxia
EA201890460A1 (ru) Композиции и способы лечения и предотвращения нейродегенеративных расстройств
MA39837B1 (fr) Quinazoline-thf-amines halogénées en tant qu'inhibiteurs de la pde1
EA201791450A1 (ru) 3,5-диаминопиразоловые ингибиторы киназы
MA39230A1 (fr) Hexahydrofuropyrroles utilisés comme inhibiteurs de pde1
MX2016008968A (es) Compuestos organicos.
EA201800565A1 (ru) Композиция для лечения заболеваний уха, содержащая (+)-азасетрон
WO2017103892A3 (en) Composition for treating and preventing neurological diseases, neuroinflammation, and alzheimer's disease
WO2016134246A3 (en) Compositions and methods for treating protein conformational diseases
EP3634410A4 (en) TAU PROTEIN PHOSPHORYLATION INHIBITORS AND METHODS OF TREATMENT OR PREVENTION OF ALZHEIMER'S DISEASE